[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
International Agency for Research on Cancer. Liver Source: Globocan 2020.
https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
|
[3]
|
Llovet, J.M., Kelley, R.K., Villanueva, A., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, 6. https://doi.org/10.1038/s41572-020-00240-3
|
[4]
|
Altekruse, S.F., Henley, S.J., Cucinelli, J.E. and McGlynn, K.A. (2014) Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States. The Ameri-can Journal of Gastroenterology, 109, 542-553.
https://doi.org/10.1038/ajg.2014.11
|
[5]
|
Xu, L., Kim, Y., Spolverato, G., et al. (2016) Racial Disparities in Treat-ment and Survival of Patients with Hepatocellular Carcinoma in the United States. Hepatobiliary Surgery and Nutrition, 5, 43-52.
|
[6]
|
Zhang, G., Li, R., Deng, Y. and Zhao, L. (2018) Conditional Survival of Patients with Hepatocellular Car-cinoma: Results from the Surveillance, Epidemiology, and End Results Registry. Expert Review of Gastroenterology & Hepatology, 12, 515-523. https://doi.org/10.1080/17474124.2018.1453806
|
[7]
|
Cheng, A.L., Kang, Y.K., Chen, Z., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
|
[8]
|
Zhu, A.X., Kang, Y.K., Yen, C.J., et al. (2019) Ramu-cirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased Alpha-Fetoprotein Concen-trations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 282-296.
|
[9]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocel-lular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[10]
|
Hinshaw, D.C. and Shevde, L.A. (2019) The Tumor Microenvi-ronment Innately Modulates Cancer Progression. Cancer Research, 79, 4557-4566. https://doi.org/10.1158/0008-5472.CAN-18-3962
|
[11]
|
Racanelli, V. and Rehermann, B. (2006) The Liver as an Immunological Organ. Hepatology, 43, S54-S62.
https://doi.org/10.1002/hep.21060
|
[12]
|
Hao, X., Sun, G., Zhang, Y., et al. (2021) Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Frontiers in Cell and Developmental Biology, 9, Article ID: 775462.
https://doi.org/10.3389/fcell.2021.775462
|
[13]
|
Li, X., et al. (2021) The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer. Nature Reviews Cancer, 21, 541-557. https://doi.org/10.1038/s41568-021-00383-9
|
[14]
|
Xue, R., Zhang, Q., Cao, Q., et al. (2022) Liver Tumour Immune Microenvironment Subtypes and Neutrophil Heterogeneity. Nature, 612, 141-147. https://doi.org/10.1038/s41586-022-05400-x
|
[15]
|
Feig, C., et al. (2013) Targeting CXCL12 from FAP-Expressing Carcinoma-Associated Fibroblasts Synergizes with Anti-PD-L1 Immunotherapy in Pancreatic Cancer. Proceedings of the National Academy of Sciences of the United States of America, 110, 20212-20217. https://doi.org/10.1073/pnas.1320318110
|
[16]
|
Chew, V., Lai, L., Pan, L., et al. (2017) Delineation of an Immuno-suppressive Gradient in Hepatocellular Carcinoma Using High-Dimensional Proteomic and Transcriptomic Analyses. Proceedings of the National Academy of Sciences of the United States of America, 114, E5900-E5909. https://doi.org/10.1073/pnas.1706559114
|
[17]
|
Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10.
https://doi.org/10.1016/j.immuni.2013.07.012
|
[18]
|
Tivol, E.A., Borriello, F., Schweitzer, A.N., et al. (1995) Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Nega-tive Regulatory Role of CTLA-4. Immunity, 3, 541-547.
https://doi.org/10.1016/1074-7613(95)90125-6
|
[19]
|
Barber, D.L., Wherry, E.J., Masopust, D., et al. (2006) Re-storing Function in Exhausted CD8 T Cells during Chronic Viral Infection. Nature, 439, 682-687. https://doi.org/10.1038/nature04444
|
[20]
|
Koyama, N., Saito, K., Nishioka, Y., et al. (2014) Pharmacodynamic Change in Plasma Angiogenic Proteins: A Dose-Escalation Phase 1 Study of the Multi-Kinase Inhibitor Lenvatinib. BMC Cancer, 14, 530.
https://doi.org/10.1186/1471-2407-14-530
|
[21]
|
Kudo, M., Finn, R.S., Qin, S., Han, K.H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.W., Han, G., Jassem, J., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1
|
[22]
|
Marino, D., Zichi, C., Audisio, M., Sperti, E. and Di Maio, M. (2019) Second-Line Treatment Options in Hepatocellular Carcinoma. Drugs Context, 8, Article ID: 212577. https://doi.org/10.7573/dic.212577
|
[23]
|
Sangro, B., Gomez-Martin, C., de la Mata, M., et al. (2013) A Clinical Tri-al of CTLA-4 Blockade with Tremelimumab in Patients with Hepatocellular Carcinoma and Chronic Hepatitis C. Journal of Hepatology, 59, 81-88.
https://doi.org/10.1016/j.jhep.2013.02.022
|
[24]
|
El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
|
[25]
|
Zhang, X., Wu, Z., Peng, Y., et al. (2021) Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. BioMed Research International, 2021, Article ID: 6651397.
https://doi.org/10.1155/2021/6651397
|
[26]
|
Yang, X., Ni, H., Lu, Z., et al. (2023) Mesenchymal Circulating Tumor Cells and Ki67: Their Mutual Correlation and Prognostic Implications in Hepatocellular Carcinoma. BMC Cancer, 23, 10.
https://doi.org/10.1186/s12885-023-10503-3
|
[27]
|
Zhang, Q., Chen, X.G., Zhou, J., et al. (2006) CD147, MMP-2, MMP-9 and MVD-CD34 Are Significant Predictors of Recurrence after Liver Transplantation in Hepatocellular Carci-noma Patients. Cancer Biology & Therapy, 5, 808-814.
https://doi.org/10.4161/cbt.5.7.2754
|
[28]
|
Yang, Y., Fu, N., Wang, H. and Hao, J. (2021) Leukocytes Infiltration Correlates Intratumoral Microvessel Density and Influence Overall and Late-Phase Disease-Free Survival in Hepatocel-lular Carcinoma. Medicine (Baltimore), 100, e28135. https://doi.org/10.1097/MD.0000000000028135
|
[29]
|
Zhang, Q., Wu, J., Bai, X. and Liang, T. (2020) Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. Frontiers in Medicine (Lausanne), 7, Article ID: 584250. https://doi.org/10.3389/fmed.2020.584250
|